Gene therapy plus oral drug for recurrent brain tumors
Part of Cancer clinical trials.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a high-grade glioma (glioblastoma or anaplastic astrocytoma) that has returned after earlier treatment (first or second time).
- You must have a specific genetic marker (DGM7) in your blood, found by a blood test.
- You have a tumor that can be seen on MRI (at least 1 centimeter in two directions).
- Your kidney function, liver function, and blood counts meet lab thresholds (for example, platelet count at least 80,000).
- You are physically active enough to have a Karnofsky performance score of 70 or higher (able to care for yourself, but may not be able to do normal activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
This trial studies a gene-based treatment (HSV-tk) given with radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. It may help the new brain tumor respond better to standard treatments, though risks and benefits are still being tested.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
This early-phase study tests a “suicide gene” therapy delivered by a virus along with radiation for adults whose high-grade brain tumor has come back or grown again. The goal is to see if the treatment is safe and can help control the tumor.
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.